These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22744966)

  • 1. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
    Suganuma R; Wang LL; Sano H; Naranjo A; London WB; Seeger RC; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Jarzembowski JA; Joshi VV; Navarro S; Peuchmaur M; Shimada H
    Pediatr Blood Cancer; 2013 Mar; 60(3):363-70. PubMed ID: 22744966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
    Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
    Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
    Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
    Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
    Okamatsu C; London WB; Naranjo A; Hogarty MD; Gastier-Foster JM; Look AT; LaQuaglia M; Maris JM; Cohn SL; Matthay KK; Seeger RC; Saji T; Shimada H
    Pediatr Blood Cancer; 2009 Oct; 53(4):563-9. PubMed ID: 19530234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
    Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
    Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.
    Tornóczky T; Kálmán E; Kajtár PG; Nyári T; Pearson AD; Tweddle DA; Board J; Shimada H
    Cancer; 2004 Jan; 100(2):390-7. PubMed ID: 14716776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.